pharma (AP Photo/Mark Lennihan)

President Joe Biden's administration says it has the authority to seize certain drug patents and license them to other manufacturers in order to lower prices — a move aimed to appeal to Americans grappling with high health-care costs.

The administration on Thursday unveiled a new framework for US agencies to use so-called march-in rights. This would allow authorities to take over the patent of some drugs that were developed with the help of taxpayer dollars and then license the invention to another entity. This step would be taken if the drug prices are deemed to be too high.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Consumer Driven Health Care
Core and Group Health
Health Care Reform
Cost-Containment
Employee Participation
Employee-Paid
Employer-Paid